NewLink Genetics Corp. (NASDAQ:NLNK) rose 2.9% during mid-day trading on Monday . The stock traded as high as $10.47 and last traded at $10.35, with a volume of 121,899 shares changing hands. The stock had previously closed at $10.06.

NLNK has been the subject of several research reports. Stifel Nicolaus lowered their price objective on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $62.00 price objective on shares of NewLink Genetics Corp. in a research report on Friday, April 29th. Mizuho lowered their price objective on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. Zacks Investment Research raised shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, July 5th. Finally, Robert W. Baird reissued a “buy” rating on shares of NewLink Genetics Corp. in a research report on Monday, May 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. NewLink Genetics Corp. currently has an average rating of “Hold” and a consensus price target of $23.29.

The firm has a 50 day moving average of $10.91 and a 200 day moving average of $14.86. The firm’s market capitalization is $298.67 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last issued its earnings results on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.35. Equities analysts expect that NewLink Genetics Corp. will post ($3.06) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in NewLink Genetics Corp. stock. Dimensional Fund Advisors LP boosted its stake in NewLink Genetics Corp. (NASDAQ:NLNK) by 0.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 48,507 shares of the company’s stock after buying an additional 300 shares during the period. Dimensional Fund Advisors LP owned 0.17% of NewLink Genetics Corp. worth $1,765,000 as of its most recent SEC filing.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.